Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient
Eur J Dermatol. 2021 Aug 26. doi: 10.1684/ejd.2021.4087. Online ahead of print.
NO ABSTRACT
PMID:34463279 | DOI:10.1684/ejd.2021.4087
Von Automat